AstraZeneca licenses inflammatory disease candidate to Allergan

October 3, 2016 6:21 AM

2 0

AstraZeneca licenses inflammatory disease candidate to Allergan

LONDON Britain's AstraZeneca said it had licensed a potential medicine for inflammatory diseases to Allergan for an upfront payment of $250 million and potential additional payments of up to $1.27 billion.

AstraZeneca said the drug developed by its global biologics research and development arm MedImmune was being testing as a treatment for moderate-to-severe Crohn's disease and was ready to start trials for ulcerative colitis.

Read more

To category page

Loading...